Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
116.60
+0.05 (+0.04%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
August 24, 2024
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with...
Via
Talk Markets
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
August 23, 2024
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and...
Via
Benzinga
Exposures
Product Safety
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
August 22, 2024
Merck's rVSV-ZEBOV vaccine, the only WHO-prequalified vaccine for Ebola outbreaks caused by the Zaire ebolavirus, is FDA-approved for adults and children. A study on the 2018–20 Congo outbreak shows...
Via
Benzinga
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
August 20, 2024
Merck's wider drug moat and acquisition spree makes it a safer bet but VKTX can be the next LLY.
Via
Talk Markets
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Merck & Co's Options: A Look at What the Big Money is Thinking
August 19, 2024
Via
Benzinga
In-Depth Analysis: Merck & Co Versus Competitors In Pharmaceuticals Industry
August 14, 2024
Via
Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
August 09, 2024
Balancing Dividends and Fundamentals: The Case of MERCK & CO. INC. (NYSE:MRK).
Via
Chartmill
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
August 18, 2024
This list of top-selling drugs could look drastically different in a few years.
Via
The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
August 15, 2024
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
The unveiled prices follow months of back-and-forth negotiation between the government and the companies.
Via
Investor's Business Daily
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
August 15, 2024
Despite a possible recession, these two Dow Jones stocks are still a buy.
Via
The Motley Fool
Topics
Economy
Stocks
Exposures
Economy
US Equities
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
August 14, 2024
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Via
InvestorPlace
Looking Into Merck & Co's Recent Short Interest
August 08, 2024
Via
Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
August 05, 2024
Via
Benzinga
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
Via
Benzinga
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
August 09, 2024
Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and...
Via
Benzinga
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
August 09, 2024
Jim Cramer recommends buying Merck (MRK) due to faith in CEO Robert Davis. He advises against Teladoc (TDOC) due to Cathie Wood's selling. He remains committed to Palo Alto Networks (PANW). He suggests...
Via
Benzinga
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
August 08, 2024
Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage small cell lung cancer due to futility in overall survival and increased...
Via
Benzinga
The 3 Best Biotech Stocks to Buy in August 2024
August 08, 2024
These biotech stocks are leading the way with groundbreaking therapies and robust fundamentals offering superb upside ahead.
Via
InvestorPlace
NYSE:MRK is an undervalued gem with solid fundamentals.
August 07, 2024
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Palantir’s AI Evolution: Strategic Shift Or Marketing Ploy?
August 06, 2024
Palantir is outgrowing government contract reliance and the AI shift is producing a robust revenue model so far.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Dividend Stocks to Buy and Never Sell
August 06, 2024
These two are rock-solid businesses with strong dividend programs.
Via
The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
August 06, 2024
Shares of the rare disease drugmaker are already up more than 40% over the past year.
Via
The Motley Fool
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
August 05, 2024
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy...
Via
Benzinga
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
August 05, 2024
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage...
Via
Benzinga
Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities
August 05, 2024
Goldman Sachs discusses Gardasil's performance in China with Merck's Joe Romanelli. Gardasil faces challenges due to market issues and partner Zhifei's operational problems, impacting Q2 sales. Despite...
Via
Benzinga
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
August 05, 2024
Moderna sustained a rare downgrade on Monday following its guidance cut for the year.
Via
Investor's Business Daily
Is It Time to Buy July's Worst-Performing Dow Jones Stocks?
August 05, 2024
Most Dow stocks were winners last month, but not these.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?
August 04, 2024
12 worst-performing large-cap stocks in the last week. Symbotic, Intel, Snap, Moderna, Mobileye, Pinterest, Arm, Entegris, Atlassian, MicroStrategy, New Oriental, and Western Digital.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.